Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Submitted by admin on September 14, 2020 - 10:21am
Source: 
Marketwatch
News Tags: 
Eli Lilly
Incyte
olumiant
COVID-19
remdesivir
Gilead Sciences
Headline: 
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
snippet: 

Eli Lily & Co. and Incyte Corp. said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s remdesivir.

Do Not Allow Advertisers to Use My Personal information